This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXMPEA601E0_M.jpg
The stock opened at $25.52 giving the company a market value of $5.62 billion.
On Wednesday, the firm priced its offering of 41.2 million shares at $18 apiece, above its expected range of $14 to $16.
Amwell had earlier planned to sell 35 million shares in its IPO.
Amwell connects and facilitates insurers, patients and innovators to deliver greater access to more affordable and higher quality medical care.
The IPO market has bounced back in recent months after a dry spell during the COVID-19 pandemic as stock markets around the world complete their recovery from coronavirus-induced lows and trade at record levels.
Boston, Massachusetts-based Amwell’s client base includes more than 240 health systems consisting of 2,000 hospitals and 55 health plan partners.
For the six months ended June 30, the company posted revenue of $122.3 million, up 77% from a year ago. Net loss attributable to the company was $111.04 million, wider than $40.7 million a year earlier.
Morgan Stanley (NYSE:MS), Goldman Sachs (NYSE:GS) & Co LLC and Piper Sandler (NYSE:PIPR) are the lead underwriters of the IPO.
